FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1459-1466 May 9, 2002 Number 19 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Dluhy, R. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The group of susceptibility genes for pheochromocytoma that included the proto-oncogene RET (associated with multiple endocrine neoplasia type 2 [MEN-2]) and the tumor-suppressor gene VHL (associated with von Hippel–Lindau disease) now also encompasses the newly identified genes for succinate dehydrogenase subunit D (SDHD) and succinate dehydrogenase subunit B (SDHB), which predispose carriers to pheochromocytomas and glomus tumors. We used molecular tools to classify a large cohort of patients with pheochromocytoma with respect to the presence or absence of mutations of one of these four genes and to investigate the relevance of genetic analyses to clinical practice.

Methods Peripheral blood from unrelated, consenting registry patients with pheochromocytoma was tested for mutations of RET, VHL, SDHD, and SDHB. Clinical data at first presentation and follow-up were evaluated.

Results Among 271 patients who presented with nonsyndromic pheochromocytoma and without a family history of the disease, 66 (24 percent) were found to have mutations (mean age, 25 years; 32 men and 34 women). Of these 66, 30 had mutations of VHL, 13 of RET, 11 of SDHD, and 12 of SDHB. Younger age, multifocal tumors, and extraadrenal tumors were significantly associated with the presence of a mutation. However, among the 66 patients who were positive for mutations, only 21 had multifocal pheochromocytoma. Twenty-three (35 percent) presented after the age of 30 years, and 17 (8 percent) after the age of 40. Sixty-one (92 percent) of the patients with mutations were identified solely by molecular testing of VHL, RET, SDHD, and SDHB; these patients had no associated signs and symptoms at presentation.

Conclusions Almost one fourth of patients with apparently sporadic pheochromocytoma may be carriers of mutations; routine analysis for mutations of RET, VHL, SDHD, and SDHB is indicated to identify pheochromocytoma-associated syndromes that would otherwise be missed.

It is a widespread assumption that most pheochromocytomas are sporadic and only about 10 percent are hereditary.¹ When hereditary, pheochromocytoma can be a component of multiple endocrine neoplasia type 2 (MEN-2), caused by mutations of the RET gene; von Hippel–Lindau disease, caused by mutations of the VHL gene; and, rarely, neurofibromatosis type 1.^2,3,4,5 Recently, mutations of the gene for succinate dehydrogenase subunit D (SDHD) were identified for another related neuroendocrine disease, familial paragangliomas of the neck, or glomus tumors.⁶ SDHD and SDHB encode mitochondrial enzymes involved in oxidative phosphorylation.⁷ In a study by Heutink et al., all 38 affected members of five original families tested had neck paragangliomas, but none had pheochromocytomas.^8,9 However, in our pilot study of pheochromocytomas from a small series comprising 17 unrelated patients with nonfamilial disease who showed no molecular or clinical evidence of MEN-2, von Hippel–Lindau disease, or neurofibromatosis type 1, we identified three unsuspected germ-line mutations of SDHD.¹⁰ In contrast, in a referral-based cohort of 19 patients with pheochromocytoma from Brazil, no mutations of SDHD were found.¹¹ In 2001, mutations of SDHB were found in three of eight families with pheochromocytoma, paraganglioma, or both.¹²

Molecular medicine makes it possible to differentiate sporadic from hereditary disease, which will affect medical management not only for the patient but also for the family. This is particularly true for inherited tumor syndromes.¹³ In the present study, we analyzed the known susceptibility genes for pheochromocytoma — VHL, RET, SDHD, and SDHB — in a large, unselected series of registry patients who presented with this tumor in order to classify them as having either truly sporadic or hereditary disease. Those who had mutations could then be reclassified as having von Hippel–Lindau disease, MEN-2, or one of the syndromes associated with pheochromocytoma and paraganglioma. In addition, we evaluated mutation status in relation to a range of clinical features to determine which, if any, can predict hereditary disease.

Methods

Patients

Patients with pheochromocytomas have been consecutively registered in the population registries of Freiburg, Germany, and Warsaw, Poland, in accordance with the ethical standards of the respective countries. Two hundred ninety-eight consecutive, unrelated patients with histologically confirmed pheochromocytoma from whom blood-leukocyte DNA was available were enrolled. All patients provided written or oral informed consent. For the purposes of registration, all cases of pheochromocytoma were included except those discovered by clinical or genetic screening of persons without symptoms of illness, in order to minimize ascertainment bias toward hereditary cases. For the purposes of this study, we excluded 11 patients with neurofibromatosis type 1, since all these patients had classic cutaneous lesions and could be easily given a diagnosis of a syndromic condition without molecular genetic analyses. We further excluded 14 patients with a family history (9 with tumors related to von Hippel–Lindau disease, and 5 with tumors related to MEN-2). DNA samples were available from 70 percent of the patients in the Freiburg registry and 88 percent of the patients in the Warsaw registry. Thus, 271 eligible registrants entered our study.

Of the 271 patients, 241 presented with pheochromocytomas only, whereas 8 presented with both pheochromocytomas and functioning paragangliomas. Twenty-two presented with paragangliomas only. Paragangliomas that originate in the sympathetic nervous system are most commonly found in the retroperitoneum but can also occur in the thorax as catecholamine-secreting, "functioning" extraadrenal pheochromocytomas (and are frequently included in the term "pheochromocytomas," which we use here). Paragangliomas that originate in the parasympathetic nervous system can occur adjacent to the aortic arch, neck, and skull base as local "nonfunctioning" masses, also called glomus tumors or chemodectomas. Unless the location of the tumor is germane, we will refer to our patients as presenting with pheochromocytoma.

Molecular Genetic Analyses

All eight exons of SDHB, all four exons of SDHD, all three exons of VHL, and exons 10, 11, and 13 through 16 of RET were examined by analysis of single-strand conformation polymorphisms and direct sequencing, as previously described.^{10,12,14,15,16,17,18}

When a patient with a germ-line mutation was identified, his or her consenting parents were investigated for the presence of the mutation; this analysis enabled us to trace the disease and the mutation back to the previous generation. If neither parent carried the index patient's mutation, we confirmed paternity using standard microsatellite fingerprinting. Genomic DNA samples from 300 anonymous, healthy blood donors matched with the registry patients for race (white) and region were analyzed as controls.

Clinical Studies

One of us performed or reviewed the clinical evaluation (personal and family history and physical examination) and medical records (detailed personal and family history, physical examination, and biochemical imaging studies). Family history was also updated at the time of blood sampling; final updates of all clinical data were performed through December 1, 2001.

Patients who were clinically or genetically identified in the present study as having a hereditary pheochromocytoma syndrome underwent clinical evaluation and surveillance for MEN-2, von Hippel–Lindau disease, and syndromes associated with pheochromocytoma and paraganglioma. The clinical screening program included measurement of serum calcitonin levels after stimulation with pentagastrin and measurement of serum parathyroid hormone levels for MEN-2; magnetic resonance imaging (MRI) of the central nervous system, MRI or computed tomography (CT) of the abdomen, and retinoscopy for von Hippel–Lindau disease²; and MRI of the abdomen, thorax, and neck for syndromes associated with pheochromocytoma and paraganglioma. The clinical diagnosis of MEN-2 required the occurrence of pheochromocytoma and medullary thyroid carcinoma.⁴ In addition to pheochromocytoma at presentation, the diagnosis of von Hippel–Lindau disease required at least angioma of the retina or hemangioblastoma of the central nervous system in the index patient or a first-degree relative.¹⁹ The diagnosis of neurofibromatosis type 1 was made according to standard criteria.⁵

Pheochromocytomas were classified according to number (solitary or multiple), location (adrenal or extraadrenal), and pathological findings (benign or malignant). Distant metastases or infiltration of surrounding tissue was required to designate a pheochromocytoma as malignant.¹

Statistical Analysis

For the comparison of rates from small samples, Fisher's (two-tailed) unpaired exact test was used; for larger groups, the standard two-sided chi-square test was used. P values less than 0.05 were considered to indicate statistical significance.

Results

A total of 271 patients (155 female and 116 male; age range, 4 to 81 years; mean age, 40 years) with nonsyndromic pheochromocytoma and without a family history of the disease were enrolled in the study. We identified 66 patients with deleterious germ-line mutations (24 percent); 13 had mutations of RET, 30 mutations of VHL, 11 mutations of SDHD, and 12 mutations of SDHB (Table 1).

View this table: [in this window] [in a new window]   Table 1. Age of the Patients and Type of Tumor at Presentation According to Genetic Status.

 
Frequency Distribution and Types of Mutations

Thirteen unrelated patients (5 percent) were found to have seven germ-line mutations of RET (Table 2). These were missense mutations, like the majority of mutations of RET associated with MEN-2 to date.²¹ Haplotype analysis to exclude a founder effect was inconclusive, but relatedness seemed unlikely on reevaluation of the family histories.

View this table: [in this window] [in a new window]   Table 2. Germ-Line Mutations in the Four Genes Detected in the Series of Patients with Pheochromocytoma.

 
The mutations of VHL in 30 patients (11 percent) comprised 3 nonsense and 19 missense mutations (Table 2). Among these 22 distinct mutations, 4 were novel. We had access to the DNA of both parents of four patients with diagnoses of pheochromocytoma (whose ages were 5, 7, 8, and 16 years). No genetic or clinical evidence of von Hippel–Lindau disease could be found in the parents, and microsatellite analysis at five different informative loci in the four families confirmed paternity. Thus, these four cases represent spontaneous germ-line mutations of VHL. Therefore, relationship of each carrier pair with the G490A and the G695A complementary DNA (cDNA) mutations (Table 2) has been excluded. The C712T cDNA mutation represents a well-known "hot spot,"²² and extensive pedigree evaluation makes it unlikely that the patients with the A680T cDNA mutation are related. It should be noted, however, that shared haplotypes usually denote ancient population-based founder effects instead of closer intermarriages that can be identified through the family history.

Eleven patients (4 percent of the 271) had seven different mutations of SDHD, three of which were novel (Table 2). Six mutations cause truncation of the putative protein, whereas one leads to a substitution of one amino acid. There were two different recurrent mutations. Haplotype analysis was inconclusive because of the small numbers, but pedigree information made relationship unlikely.

Twelve patients (4 percent) were found to have nine distinct, novel mutations of SDHB (Table 2). There were three recurrent mutations, none of which occurred in shared haplotypes; extensive pedigree evaluation also demonstrated that it was unlikely that any of the three carrier pairs were related.

None of the seven mutations of SDHD or the nine mutations of SDHB found in our patients were found in 600 control chromosomes from the 300 blood donors.

Clinical Presentation and Follow-up of Carriers

The age at the onset of symptoms was statistically lower in all carriers of mutations than in patients with sporadic disease, who were operationally defined as negative for mutations of any of the four susceptibility genes. Seventy percent of the patients who presented at the age of 10 or younger had germ-line mutations, and this percentage decreased steadily with increasing age to 0 percent among patients who presented after the age of 60 (Table 3). However, 139 registrants presented with pheochromocytoma after the age of 40, 11 of whom had mutations (8 percent). Only five of these patients had clinical findings that retrospectively suggested a hereditary pheochromocytoma. Mutations of VHL were present in 42 percent of all those who presented at age 18 or younger (20 of 48) and 74 percent of all patients with mutations who presented at age 18 or younger (20 of 27); 77 percent of those found to have mutations of VHL presented before the age of 20 (Table 3). In contrast, 9 of the 23 patients found to have germ-line mutations of SDHD and SDHB (39 percent) presented after the age of 30.

View this table: [in this window] [in a new window]   Table 3. Age at Presentation of Patients with Mutations or Sporadic Disease.

 
At initial presentation, 45 of 66 probands with mutations (68 percent) had only one tumor (Table 1). Multiple pheochromocytomas, however, were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 [32 percent] vs. 5 of 205 [2 percent], P<0.001). However, multifocal tumors, as compared with solitary tumors, may be gene-specific: no patients with mutations of SDHB presented with multifocal disease, whereas 40 percent of those with mutations of VHL had multifocal disease. Twenty-eight percent of the patients with mutations of VHL, SDHD, and SDHB had extraadrenal tumors, as compared with 8 percent of patients without mutations (P=0.006).

We also identified classic syndrome-associated lesions at presentation and at final follow-up. Of 13 patients who were positive for mutations of RET, none had clinical evidence of medullary thyroid carcinoma at presentation, but medullary thyroid carcinoma developed in 12 during the follow-up period. Among 30 carriers of mutations of VHL, 5 also subsequently had other features associated with von Hippel–Lindau disease, such as hemangioblastoma of the central nervous system or eye, pancreatic cysts, islet-cell tumors, or renal-cell carcinomas, during follow-up. In total, 10 patients were found to have associated lesions during follow-up. Of 23 carriers of SDHD or SDHB mutations, none had glomus tumors at presentation, but these tumors developed in 4 patients during follow-up (Figure 1). The majority of medullary thyroid carcinomas and glomus tumors were detected by screening.

View larger version (60K): [in this window] [in a new window]   Figure 1. Pheochromocytoma of the Left Adrenal Gland and Glomus Tumor of the Left Carotid Body in a Carrier of a Mutation of SDHD. The pheochromocytoma became symptomatic five years earlier than the glomus tumor. In Panel A, transverse T2-weighted abdominal MRI shows a hyperintense left adrenal pheochromocytoma (arrow). In Panel B, contrast-enhanced transverse cervical MRI (T1-weighted images with spectral fat saturation) reveals a contrast-enhancing left cervical glomus tumor (arrows).

 
Because of our exclusion criteria, none of the 66 patients who were positive for mutations presented with a family history of syndrome-specific tumors. However, among patients with mutations of RET, six had a positive family history at the final follow-up. Similarly, 12 carriers of mutations of VHL had a positive family history at follow-up. None of the 23 patients found to have germ-line mutations of SDHD or SDHB had a positive family history at initial presentation. Even at follow-up, only four had family members who had been found to have clinical disease. There was a delay of up to 35 years before relatives began to have symptoms, and for 10 of 23 patients, the family history became positive only when active clinical screening was performed. Forty-two of the 66 probands with mutations (64 percent) had only one pheochromocytoma and no associated syndrome-specific lesion. Over 80 percent of patients with mutations of SDHD (7 of 11) or SDHB (12 of 12) presented with one pheochromocytoma, no family history, and no feature of associated syndromes. In contrast, this was true in about half of the patients with mutations of RET (8 of 13) or VHL (15 of 30).

Discussion

Our systematic clinical and molecular evaluation of 271 unrelated patients who presented with nonsyndromic pheochromocytoma revealed that 66 (24 percent) had a hereditary predisposition to von Hippel–Lindau disease, MEN-2, or the syndromes associated with pheochromocytoma and paraganglioma on the basis of newly discovered mutations in the VHL, RET, SDHD, or SDHB gene. Among the 66 patients with mutations, 45 percent had germ-line mutations of VHL, 20 percent had mutations of RET, and 17 and 18 percent had mutations of two newly identified genes, SDHD and SDHB. Currently, 64 percent of all probands found to have hereditary disease were identified with the use of molecular testing of VHL, RET, SDHD, and SDHB and had no family history, solitary disease, and no associated signs and symptoms at presentation.

Several previous studies, limited by small size, hinted that certain subgroups of patients with pheochromocytoma might have a higher risk of hereditary disease — those with bilateral or multifocal tumors, those who are relatively young at presentation, or both.^2,4,23,24 Our registry-based study addresses these issues by its complete or nearly complete identification of virtually all cases of bilateral tumors, cases of extraadrenal pheochromocytoma (paraganglioma), and cases with early onset. We can state confidently that 84 percent of all multifocal tumors (including bilateral tumors) and 59 percent of pheochromocytomas with onset at the age of 18 years or younger were found to be hereditary. Our results suggest that extraadrenal pheochromocytoma may be a striking feature of hereditary disease (P=0.006). When extraadrenal disease is found either in isolation or with adrenal pheochromocytoma, the molecular differential diagnosis, in descending order, includes mutations of SDHB (in 50 percent of cases), SDHD (36 percent), and VHL (17 percent) but not RET.

A partial explanation for the high frequency of hereditary pheochromocytoma without a family history of disease might include spontaneous mutation in one of the susceptibility genes, decreased penetrance, and maternal imprinting. In our registry, spontaneous mutations in VHL accounted for 13 percent of cases of hereditary von Hippel–Lindau disease. Penetrance is known to be relatively high (approximately 70 percent by the age of 70) among patients with MEN-2 and von Hippel–Lindau disease, overall.^25,26 The penetrance of mutations of SDHD and SDHB is not well known because they are newly identified genes. Preliminary figures from this registry suggest a relatively high penetrance. Familial glomus tumors due to mutations of SDHD are known to be maternally imprinted.^6,9 Overall, therefore, pheochromocytomas in patients without family histories are due to spontaneous mutations, decreased penetrance, or maternal imprinting, although other causes such as gene–gene interactions and gene–environment interactions may be possible.

Genetic testing can be a powerful aid to the identification of a syndrome in such cases. For example, our study suggests that a patient with pheochromocytoma who has mutations of SDHD or SDHB has an approximately 20 to 30 percent likelihood of already having glomus tumors or of having glomus tumors develop. Since such tumors are difficult to treat when advanced (Figure 1), it is reasonable to speculate that molecular identification of a mutation in one of these two genes could lead to surveillance, early diagnosis of tumors, and more effective treatment. In our study, 68 percent of patients found to have germ-line mutations presented with solitary tumors. It is the standard of care for clinical cancer geneticists to offer genetic testing to patients with a minimal a priori risk of mutation of 10 percent.¹³ This figure can be lowered if the technique of mutation analysis is straightforward and cost effective and the alteration in medical management saves lives, as is the case for testing for mutations of RET.²⁷ Our registry-based study has demonstrated that the a priori risk of finding a mutation of VHL, RET, SDHD, or SDHB in unrelated patients who present with pheochromocytoma not only meets but exceeds both of these criteria, even in the case of patients who are over the age of 40 at presentation.

In our opinion, although it has not yet been demonstrated by a clinical trial, the identification of a new case of hereditary pheochromocytoma on the basis of the identification of the disease-associated mutation should prompt genetic testing of all first-degree relatives of the carrier to determine the presence or absence of the family-specific mutation. Since disease is likely to develop in virtually all patients with a family-specific mutation, it seems reasonable to subject such patients to lifelong surveillance, prophylactic surgery, or both, depending on the precise genetic diagnosis.

Supported by grants from the Center of Clinical Research (3000 1257 C5) of the Albert Ludwigs University, the Deutsche Forschungsgemeinschaft (NE 571/4-1), the Polish Committee of Scientific Research (4PO5B813), and the National Institutes of Health (R01HD39058 and P30CA16058).

We are indebted to Bettina Bohnert-Iwan, Juliane Alt-Moerbe, Ph.D., Heather Dziema, B.A., Jessica L. Brown, B.A., and Mary Armanios, M.D., for technical assistance; to Gabriele Reifsteck for secretarial assistance; to Christian Ketterer for biostatistical assistance; to the many clinicians of the Freiburg–Warsaw–Columbus Pheochromocytoma Study Group for their continued support; to Eva Wey-Vogel, Ph.D., and Alessandra Baumer, M.D., for contributing the control DNA; to many colleagues and families for detailed information; and to Michael R. Grever, Ph.D., for critical review of an early draft of the manuscript.

^* The members of the Freiburg–Warsaw–Columbus Pheochromocytoma Study Group are listed in the Appendix.

Source Information

From the Department of Nephrology and Hypertension (H.P.H.N., B.B., B.U.B., G.F.), the Department of Otolaryngology (J.S.), the Department of Neuroradiology (J.K.), and the Department of Radiology (C.A.), Albert Ludwigs University, Freiburg, Germany; the Clinical Cancer Genetics Program and Human Cancer Genetics Program, Comprehensive Cancer Center, and Division of Human Genetics, Department of Internal Medicine, Ohio State University, Columbus (S.R.M., O.G., C.E.); the Institute of Human Genetics, University of Aachen, Aachen, Germany (K.Z.); the Department of Hypertension, Institute of Cardiology, Warsaw, Poland (A.J.); and the Cancer Research Campaign, Human Cancer Genetics Research Group, University of Cambridge, Cambridge, United Kingdom (C.E.).

Drs. Neumann and Eng contributed equally to the article.

Other authors were Wendy M. Smith, B.A. (Human Cancer Genetics Program, Ohio State University, Columbus); Robin Munk, M.D., Tanja Manz, M.D., Sven Glaesker, M.D., and Thomas W. Apel, Ph.D. (Department of Nephrology, Clinics of the Albert Ludwigs University, Freiburg, Germany); Markus Treier, M.D. (Department of Otolaryngology, Clinics of the Albert Ludwigs University, Freiburg, Germany); Martin Reineke, M.D. (Department of Gastroenterology and Endocrinology, Clinics of the Albert Ludwigs University, Freiburg, Germany); Martin K. Walz, M.D. (Department of Surgery, Klinikum Essen-Mitte, Essen, Germany); Cuong Hoang-Vu, M.D., and Michael Brauckhoff, M.D. (Department of Surgery, University of Halle, Halle, Germany); Andreas Klein-Franke, M.D. (Department of Pediatrics, University of Göttingen, Göttingen, Germany); Peter Klose, M.D. (Department of Pediatrics, City Hospital, Munich-Harlaching, Germany); Heinrich Schmidt, M.D. (Department of Pediatrics, Ludwig-Maximilians University, Munich, Germany); Margarete Maier-Woelfle, M.D. (Department of Internal Medicine, Kantonsspital, St. Gallen, Switzerland); Mariola Peçzkowska, M.D. (Department of Hypertension, Institute of Cardiology, Warsaw, Poland); and Cesary Szmigielski, M.D. (Medical University, Warsaw, Poland).

Address reprint requests to Dr. Neumann at the Medizinische Universitätsklinik, Hugstetterstr. 55, D-79106 Freiburg, Germany, or at neumann{at}mm41.ukl.uni-freiburg.de.

References

1. Manger WM, Gifford RW Jr. Pheochromocytoma: a clinical overview. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. Vol. 2. New York: Raven Press, 1995:2225-44. 
2. Neumann HPH, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531-1538. [Erratum, N Engl J Med 1994;331:1535.] [Free Full Text]
3. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999;162:659-664. [CrossRef][Web of Science][Medline]
4. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996;335:943-951. [Free Full Text]
5. Eng C, Maher ER. Dominant genes and phakomatoses associated with multiple primary cancers. In: Neugut AI, Meadows AT, Robinson E, eds. Multiple primary cancers. Philadelphia: Lippincott Williams & Wilkins, 1999:165-95.
6. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-851. [Free Full Text]
7. Nakamura K, Yamaki M, Sarada M, et al. Two hydrophobic subunits are essential for the heme b ligation and functional assembly of complex II (succinate-ubiquinone oxidoreductase) from Escherichia coli. J Biol Chem 1996;271:521-527. [Free Full Text]
8. Heutink P, van Schothorst EM, van der Mey AGL, et al. Further localization of the gene for hereditary paragangliomas and evidence for linkage in unrelated families. Eur J Hum Genet 1994;2:148-158. [Medline]
9. Heutink P, van der Mey AGL, Sandkuijl LA, et al. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet 1992;1:7-10. [Free Full Text]
10. Gimm O, Armanios M, Dziema H, Neumann HPH, Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000;60:6822-6825. [Free Full Text]
11. Aguiar RCT, Cox G, Pomeroy SL, Dahia PLM. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab 2001;86:2890-2894. [Free Full Text]
12. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49-54. [CrossRef][Web of Science][Medline]
13. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:1730-1736. [Free Full Text]
14. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320. [Free Full Text]
15. Mulligan LM, Eng C, Attié T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994;3:2163-2167. [Free Full Text]
16. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-241. [Erratum, Hum Mol Genet 1994;3:686.] [Free Full Text]
17. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-513. [Web of Science][Medline]
18. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10:2415-2419. [Web of Science][Medline]
19. Neumann HPH. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 1987;16:220-226. [Web of Science][Medline]
20. Glavac D, Neumann HPH, Wittke C, et al. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet 1996;98:271-280. [CrossRef][Web of Science][Medline]
21. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996;276:1575-1579. [Free Full Text]
22. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-357. [CrossRef][Web of Science][Medline]
23. Eng C, Crossey PA, Mulligan LM, et al. Mutations of the RET proto-oncogene and the von Hippel-Lindau disease tumor suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995;32:934-937. [Free Full Text]
24. Woodward ER, Eng C, McMahon R, et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 1997;6:1051-1056. [Free Full Text]
25. Ponder BAJ, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988;1:397-401. [Web of Science][Medline]
26. Bender BU, Eng C, Olschewski M, et al. VHL c.505T>C mutation confers a high age related penetrance but no increased overall mortality. J Med Genet 2001;38:508-514. [Free Full Text]
27. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380-393. [Free Full Text]

The members of the Freiburg–Warsaw–Columbus Pheochromocytoma Study Group were as follows (all are in Germany unless otherwise indicated): B. Allolio, Department of Endocrinology, University of Wuerzburg, Wuerzburg; M. Andrino, University of Essen, Essen; F.A.M. Baumeister, Department of Pediatrics, Munich Technical University, Munich; Alessandra Baumer, Department of Genetics, University of Zurich, Zurich, Switzerland; D.P. Berger, Department of Oncology, University of Freiburg, Freiburg; P. Beyer, Children's Hospital, Evangelisches Krankenhaus, Oberhausen; E. Blind, Department of Medicine–Endocrinology, University of Wuerzburg, Wuerzburg; P. Bucsky, Department of Pediatrics, University of Luebeck, Luebeck; K. Cupisti, Department of General and Trauma Surgery, University of Düsseldorf, Düsseldorf; I. Cybulska, Department of Hypertension, Institute of Cardiology, Warsaw, Poland; H. Dahan, Institute of Human Genetics, Université Catholique de Louvain Bruxelles, Brussels, Belgium; H.G. Doerr, Department of Pediatrics, University of Erlangen, Erlangen; M. Domula, Department of Pediatrics, LM University of Leipzig, Leipzig; W. Draf, Department of Otolaryngology, City Hospital, Fulda; H. Dralle, Department of General, Visceral and Vascular Surgery, University of Halle, Halle; R. Elsner, University of Munich, Munich; J. Engert, Department of Pediatric Surgery, Marienhospital, University of Bochum, Bochum; W. Fassbinder, Department of Internal Medicine, City Hospital, Fulda; A. Frilling, Department of Surgery and Transplantation, University of Essen, Essen; P. Heidemann, Children's Hospital, Augsburg; S. Hoegerle, Department of Nuclear Medicine, University of Freiburg, Freiburg; G. Hofmockel, Department of Urology, Medizinisches Zentrum, Wuerselen; W. Januszewicz, Warsaw, Poland; A. Jocham, Ludwig-Maximilians University, Munich; H. Juergens, Department of Pediatrics, University of Muenster, Muenster; H. Kabisch, Department of Pediatrics, University of Hamburg, Hamburg; G. Kirste, Department of Surgery, University of Freiburg, Freiburg; B. Kratzsch, Department of Otolaryngology, City Hospital, Fulda; I. Krause, Children's Hospital, Chemnitz; B. Kremens, Department of Pediatrics, University of Essen, Essen; K.M. Kreusel, Department of Ophthalmology, Free University, Berlin; H. Krude, Department of Pediatric Endocrinology, Charité, Berlin; B. Krumme, Deutsche Klinik fuer Diagnostik, Wiesbaden; M. Lapinski, Medical University, Warsaw, Poland; J. Laubenberger, Department of Radiology, University of Freiburg, Freiburg; S. Lederbogen, Essen; H.G. Lenard, Department of Pediatrics, University of Düsseldorf, Düsseldorf; I. Lon, Medical University, Warsaw, Poland; M. Makowiecka-Ciesla, Department of Hypertension, Institute of Cardiology, Warsaw, Poland; K. Mann, Department of Endocrinology, University of Essen, Essen; O. Mehls, Department of Pediatrics, University of Heidelberg, Heidelberg; U. Mittler, Department of Pediatric Oncology and Hematology, University of Magdeburg, Magdeburg; O.A. Mueller, Rotkreuz Hospital, Munich; L.M. Neumann, Department of Human Genetics, Charite, Campus Virchow, Humboldt University, Berlin; C.M. Niemeyer, Department of Pediatrics, University of Freiburg, Freiburg; H.H. Peter, Department of Rheumatology and Immunology, University of Freiburg, Freiburg; W. Rabl, Department of Pediatrics, Technical University of Munich, Munich; P. Reichardt, Department of Pediatric Surgery, University of Leipzig, Leipzig; K.D. Rueckauer, Department of Surgery, University of Freiburg, Freiburg; A. Schinzel, Department of Genetics, University of Zurich, Zurich, Switzerland; D. Schmidt, Department of Ophthalmology, University of Freiburg, Freiburg; M. Schoeniger, Department of Pediatrics, City Hospital, Munich-Schwabing, Munich; W. Schultze-Seemann, Department of Urology, University of Freiburg, Freiburg; D. Simon, Department of Surgery, University of Düsseldorf, Düsseldorf; W.G. Sippel, Department of Pediatrics, University of Kiel, Kiel; M. Stahl, Children's Hospital, Loerrach; M. Sznajderman, Department of Hypertension, Institute of Cardiology, Warsaw, Poland; C. Verellen, Center of Human Genetics, Université Catholique de Louvain Bruxelles, Brussels, Belgium; H. Wehinger, Children's Hospital Kassel, Kassel; R.R. Wenzel, Department of Nephrology, University of Essen, Essen; U. Wetterauer, Department of Urology, University of Freiburg, Freiburg; B. Wocial, Medical University, Warsaw, Poland; S.A. Wudy, Department of Pediatrics, University of Giessen, Giessen; L.B. Zimmerhackl, Department of Pediatrics, University of Freiburg, Freiburg; O. Zimmermann, Children's Hospital, Chemnitz; W. Zumkeller, Children's Hospital, University of Halle, Halle.

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Dluhy, R. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Strauchen J. A., Neumann H. P.H., Schipper J., Eng C.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:854-855, Sep 12, 2002. Correspondence

This article has been cited by other articles:

• Erlic, Z., Rybicki, L., Peczkowska, M., Golcher, H., Kann, P. H., Brauckhoff, M., Mussig, K., Muresan, M., Schaffler, A., Reisch, N., Schott, M., Fassnacht, M., Opocher, G., Klose, S., Fottner, C., Forrer, F., Plockinger, U., Petersenn, S., Zabolotny, D., Kollukch, O., Yaremchuk, S., Januszewicz, A., Walz, M. K., Eng, C., Neumann, H. P.H., for the European-American Pheochromocytoma Study G, (2009). Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clin. Cancer Res. 15: 6378-6385 [Abstract] [Full Text]  
• Bayley, J.-P., Weiss, M. M, Grimbergen, A., van Brussel, B. T J, Hes, F. J, Jansen, J. C, Verhoef, S., Devilee, P., Corssmit, E. P, Vriends, A. H J T (2009). Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients. Endocr Relat Cancer 16: 929-937 [Abstract] [Full Text]  
• Gergics, P., Patocs, A., Toth, M., Igaz, P., Szucs, N., Liko, I., Fazakas, F., Szabo, I., Kovacs, B., Glaz, E., Racz, K. (2009). Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol 161: 495-502 [Abstract] [Full Text]  
• Neumann, H. P. H., Eng, C. (2009). The Approach to the Patient with Paraganglioma. J. Clin. Endocrinol. Metab. 94: 2677-2683 [Abstract] [Full Text]  
• Turner, S. T., Fornage, M., Jack, C. R. Jr, Mosley, T. H., Knopman, D. S., Kardia, S. L. R., Boerwinkle, E., de Andrade, M. (2009). Genomic Susceptibility Loci for Brain Atrophy, Ventricular Volume, and Leukoaraiosis in Hypertensive Sibships. Arch Neurol 66: 847-857 [Abstract] [Full Text]  
• van Nederveen, F. H, Korpershoek, E., deLeeuw, R. J, Verhofstad, A. A, Lenders, J. W, Dinjens, W. N M, Lam, W. L, de Krijger, R. R (2009). Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocr Relat Cancer 16: 505-513 [Abstract] [Full Text]  
• Timmers, H. J L M, Gimenez-Roqueplo, A.-P., Mannelli, M., Pacak, K. (2009). Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 16: 391-400 [Abstract] [Full Text]  
• Srirangalingam, U., Khoo, B., Walker, L., MacDonald, F., Skelly, R. H, George, E., Spooner, D., Johnston, L. B, Monson, J. P, Grossman, A. B, Drake, W M, Akker, S. A, Pollard, P. J, Plowman, N., Avril, N., Berney, D. M, Burrin, J. M, Reznek, R. H, Kumar, V K A., Maher, E. R, Chew, S. L (2009). Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 16: 515-525 [Abstract] [Full Text]  
• Boedeker, C. C., Erlic, Z., Richard, S., Kontny, U., Gimenez-Roqueplo, A.-P., Cascon, A., Robledo, M., de Campos, J. M., van Nederveen, F. H., de Krijger, R. R., Burnichon, N., Gaal, J., Walter, M. A., Reschke, K., Wiech, T., Weber, J., Ruckauer, K., Plouin, P. F., Darrouzet, V., Giraud, S., Eng, C., Neumann, H. P. H. (2009). Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. J. Clin. Endocrinol. Metab. 94: 1938-1944 [Abstract] [Full Text]  
• Malik, A. A., Houni, A. E., Gulshad, H., Elsiah, S., Al-Salam, S. (2009). An interesting case of paraganglioma. BMJ Case Reports 2009: bcr1020081150-bcr1020081150 [Full Text]  
• Mannelli, M., Castellano, M., Schiavi, F., Filetti, S., Giacche, M., Mori, L., Pignataro, V., Bernini, G., Giache, V., Bacca, A., Biondi, B., Corona, G., Di Trapani, G., Grossrubatscher, E., Reimondo, G., Arnaldi, G., Giacchetti, G., Veglio, F., Loli, P., Colao, A., Ambrosio, M. R., Terzolo, M., Letizia, C., Ercolino, T., Opocher, G., the Italian Pheochromocytoma/Paraganglioma Network, (2009). Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. J. Clin. Endocrinol. Metab. 94: 1541-1547 [Abstract] [Full Text]  
• Cascon, A., Pita, G., Burnichon, N., Landa, I., Lopez-Jimenez, E., Montero-Conde, C., Leskela, S., Leandro-Garcia, L. J., Leton, R., Rodriguez-Antona, C., Diaz, J. A., Lopez-Vidriero, E., Gonzalez-Neira, A., Velasco, A., Matias-Guiu, X., Gimenez-Roqueplo, A.-P., Robledo, M. (2009). Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients. J. Clin. Endocrinol. Metab. 94: 1701-1705 [Abstract] [Full Text]  
• Taieb, D., Sebag, F., Barlier, A., Tessonnier, L., Palazzo, F. F., Morange, I., Niccoli-Sire, P., Fakhry, N., De Micco, C., Cammilleri, S., Enjalbert, A., Henry, J.-F., Mundler, O. (2009). 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature?. JNM 50: 711-717 [Abstract] [Full Text]  
• Neumann, H. P.H., Erlic, Z., Boedeker, C. C., Rybicki, L. A., Robledo, M., Hermsen, M., Schiavi, F., Falcioni, M., Kwok, P., Bauters, C., Lampe, K., Fischer, M., Edelman, E., Benn, D. E., Robinson, B. G., Wiegand, S., Rasp, G., Stuck, B. A., Hoffmann, M. M., Sullivan, M., Sevilla, M. A., Weiss, M. M., Peczkowska, M., Kubaszek, A., Pigny, P., Ward, R. L., Learoyd, D., Croxson, M., Zabolotny, D., Yaremchuk, S., Draf, W., Muresan, M., Lorenz, R. R., Knipping, S., Strohm, M., Dyckhoff, G., Matthias, C., Reisch, N., Preuss, S. F., Esser, D., Walter, M. A., Kaftan, H., Stover, T., Fottner, C., Gorgulla, H., Malekpour, M., Zarandy, M. M., Schipper, J., Brase, C., Glien, A., Kuhnemund, M., Koscielny, S., Schwerdtfeger, P., Valimaki, M., Szyfter, W., Finckh, U., Zerres, K., Cascon, A., Opocher, G., Ridder, G. J., Januszewicz, A., Suarez, C., Eng, C. (2009). Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Res. 69: 3650-3656 [Abstract] [Full Text]  
• Pigny, P., Cardot-Bauters, C., Do Cao, C., Vantyghem, M. C., Carnaille, B., Pattou, F., Caron, P., Wemeau, J.-L., Porchet, N. (2009). Should genetic testing be performed in each patient with sporadic pheochromocytoma at presentation?. Eur J Endocrinol 160: 227-231 [Abstract] [Full Text]  
• Ladroue, C., Carcenac, R., Leporrier, M., Gad, S., Le Hello, C., Galateau-Salle, F., Feunteun, J., Pouyssegur, J., Richard, S., Gardie, B. (2008). PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma. NEJM 359: 2685-2692 [Abstract] [Full Text]  
• Milos, I. N, Frank-Raue, K., Wohllk, N., Maia, A. L., Pusiol, E., Patocs, A., Robledo, M., Biarnes, J., Barontini, M., Links, T. P, de Groot, J. W., Dvorakova, S., Peczkowska, M., Rybicki, L. A, Sullivan, M., Raue, F., Zosin, I., Eng, C., Neumann, H. P H (2008). Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocr Relat Cancer 15: 1035-1041 [Abstract] [Full Text]  
• Peczkowska, M., Erlic, Z., Hoffmann, M. M., Furmanek, M., Cwikla, J., Kubaszek, A., Prejbisz, A., Szutkowski, Z., Kawecki, A., Chojnowski, K., Lewczuk, A., Litwin, M., Szyfter, W., Walter, M. A., Sullivan, M., Eng, C., Januszewicz, A., Neumann, H. P. H. (2008). Impact of Screening Kindreds for SDHD p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1. J. Clin. Endocrinol. Metab. 93: 4818-4825 [Abstract] [Full Text]  
• Baysal, B E (2008). Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet. 45: 689-694 [Abstract] [Full Text]  
• Armstrong, R, Sridhar, M, Greenhalgh, K L, Howell, L, Jones, C, Landes, C, McPartland, J L, Moores, C, Losty, P D, Didi, M (2008). Phaeochromocytoma in children. Arch. Dis. Child. 93: 899-904 [Abstract] [Full Text]  
• Eng, C. (2008). SDHB--A Gene for All Tumors?. JNCI J Natl Cancer Inst 100: 1193-1195 [Full Text]  
• Margetts, C. D E, Morris, M., Astuti, D., Gentle, D. C, Cascon, A., McRonald, F. E, Catchpoole, D., Robledo, M., Neumann, H. P H, Latif, F., Maher, E. R (2008). Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocr Relat Cancer 15: 777-786 [Abstract] [Full Text]  
• Adler, J. T., Meyer-Rochow, G. Y., Chen, H., Benn, D. E., Robinson, B. G., Sippel, R. S., Sidhu, S. B. (2008). Pheochromocytoma: Current Approaches and Future Directions. The Oncologist 13: 779-793 [Abstract] [Full Text]  
• Kiss, N B, Geli, J, Lundberg, F, Avci, C, Velazquez-Fernandez, D, Hashemi, J, Weber, G, Hoog, A, Ekstrom, T J, Backdahl, M, Larsson, C (2008). Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Endocr Relat Cancer 15: 609-621 [Abstract] [Full Text]  
• Kennelly, R., Aziz, R., Toner, M., Young, V. (2008). Right atrial paraganglioma: an unusual primary cardiac tumour. Eur. J. Cardiothorac. Surg. 33: 1150-1152 [Abstract] [Full Text]  
• Geli, J., Kiss, N., Karimi, M., Lee, J.-J., Backdahl, M., Ekstrom, T. J., Larsson, C. (2008). Global and Regional CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas: Association to Malignant Behavior. Clin. Cancer Res. 14: 2551-2559 [Abstract] [Full Text]  
• Weber, F., Eng, C. (2008). Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare?. J. Clin. Endocrinol. Metab. 93: 1097-1104 [Abstract] [Full Text]  
• Yuan, W., Wang, W., Cui, B., Su, T., Ge, Y., Jiang, L., Zhou, W., Ning, G. (2008). Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer 15: 343-350 [Abstract] [Full Text]  
• Kanaan, N., Persu, A., Van Ingelgem, G., Malaise, J., Goffin, E. (2008). Recurrent pulmonary oedema and severe hypertension after renal transplantation: other reasons than renal artery stenosis. Nephrol Dial Transplant 23: 397-399 [Full Text]  
• Karagiannis, A., Mikhailidis, D. P, Athyros, V. G, Harsoulis, F. (2007). Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 14: 935-956 [Abstract] [Full Text]  
• Thouennon, E., Elkahloun, A. G., Guillemot, J., Gimenez-Roqueplo, A.-P., Bertherat, J., Pierre, A., Ghzili, H., Grumolato, L., Muresan, M., Klein, M., Lefebvre, H., Ouafik, L., Vaudry, H., Plouin, P.-F., Yon, L., Anouar, Y. (2007). Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy. J. Clin. Endocrinol. Metab. 92: 4865-4872 [Abstract] [Full Text]  
• Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., Plouin, P.-F. (2007). Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas. J. Clin. Endocrinol. Metab. 92: 3822-3828 [Abstract] [Full Text]  
• Neumann, H. P.H., Vortmeyer, A., Schmidt, D., Werner, M., Erlic, Z., Cascon, A., Bausch, B., Januszewicz, A., Eng, C. (2007). Evidence of MEN-2 in the Original Description of Classic Pheochromocytoma. NEJM 357: 1311-1315 [Abstract] [Full Text]  
• Mannelli, M, Ercolino, T, Giache, V, Simi, L, Cirami, C, Parenti, G (2007). Genetic screening for pheochromocytoma: should SDHC gene analysis be included?. J. Med. Genet. 44: 586-587 [Abstract] [Full Text]  
• van Nederveen, F. H., Korpershoek, E., Lenders, J. W.M., de Krijger, R. R., Dinjens, W. N.M. (2007). Somatic SDHB Mutation in an Extraadrenal Pheochromocytoma. NEJM 357: 306-308 [Full Text]  
• Bausch, B., Borozdin, W., Mautner, V. F., Hoffmann, M. M., Boehm, D., Robledo, M., Cascon, A., Harenberg, T., Schiavi, F., Pawlu, C., Peczkowska, M., Letizia, C., Calvieri, S., Arnaldi, G., Klingenberg-Noftz, R. D., Reisch, N., Fassina, A., Brunaud, L., Walter, M. A., Mannelli, M., MacGregor, G., Palazzo, F. F., Barontini, M., Walz, M. K., Kremens, B., Brabant, G., Pfaffle, R., Koschker, A.-C., Lohoefner, F., Mohaupt, M., Gimm, O., Jarzab, B., McWhinney, S. R., Opocher, G., Januszewicz, A., Kohlhase, J., Eng, C., Neumann, H. P. H., for the European-American Phaeochromocytoma Regist, (2007). Germline NF1 Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. J. Clin. Endocrinol. Metab. 92: 2784-2792 [Abstract] [Full Text]  
• Brouwers, F. M, Glasker, S., Nave, A. F, Vortmeyer, A. O, Lubensky, I., Huang, S., Abu-Asab, M. S, Eisenhofer, G., Weil, R. J, Park, D. M, Linehan, W M., Pacak, K., Zhuang, Z. (2007). Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocr Relat Cancer 14: 463-471 [Abstract] [Full Text]  
• Scholz, T., Eisenhofer, G., Pacak, K., Dralle, H., Lehnert, H. (2007). Current Treatment of Malignant Pheochromocytoma. J. Clin. Endocrinol. Metab. 92: 1217-1225 [Abstract] [Full Text]  
• Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., Pacak, K. (2007). Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. J. Clin. Endocrinol. Metab. 92: 779-786 [Abstract] [Full Text]  
• Chak, A., Ochs-Balcom, H., Falk, G., Grady, W. M., Kinnard, M., Willis, J. E., Elston, R., Eng, C. (2006). Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction.. Cancer Epidemiol. Biomarkers Prev. 15: 1668-1673 [Abstract] [Full Text]  
• Bausch, B., Koschker, A.-C., Fassnacht, M., Stoevesandt, J., Hoffmann, M. M., Eng, C., Allolio, B., Neumann, H. P. H. (2006). Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma. J. Clin. Endocrinol. Metab. 91: 3478-3481 [Abstract] [Full Text]  
• Pham, T. H., Moir, C., Thompson, G. B., Zarroug, A. E., Hamner, C. E., Farley, D., van Heerden, J., Lteif, A. N., Young, W. F. Jr (2006). Pheochromocytoma and Paraganglioma in Children: A Review of Medical and Surgical Management at a Tertiary Care Center. Pediatrics 118: 1109-1117 [Abstract] [Full Text]  
• de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., Hofstra, R. M. W. (2006). RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors. Endocr. Rev. 27: 535-560 [Abstract] [Full Text]  
• Jimenez, C., Cote, G., Arnold, A., Gagel, R. F. (2006). Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?. J. Clin. Endocrinol. Metab. 91: 2851-2858 [Abstract] [Full Text]  
• Iliopoulos, O., Chan-Smutko, G., Gonzalez, R. G., Louis, D. N., Stone, J. R. (2006). Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the right hand and hypertension.. NEJM 355: 394-402 [Full Text]  
• Wang, Q., Diskin, S., Rappaport, E., Attiyeh, E., Mosse, Y., Shue, D., Seiser, E., Jagannathan, J., Shusterman, S., Bansal, M., Khazi, D., Winter, C., Okawa, E., Grant, G., Cnaan, A., Zhao, H., Cheung, N.-K., Gerald, W., London, W., Matthay, K. K., Brodeur, G. M., Maris, J. M. (2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.. Cancer Res. 66: 6050-6062 [Abstract] [Full Text]  
• Woodward, E. R, Maher, E. R (2006). Von Hippel-Lindau disease and endocrine tumour susceptibility.. Endocr Relat Cancer 13: 415-425 [Abstract] [Full Text]  
• Maher, E. R. (2006). Genetics of phaeochromocytoma. Br Med Bull 79-80: 141-151 [Abstract] [Full Text]  
• Young, W. F. Jr, Abboud, A. L. (2006). Paraganglioma--all in the family.. J. Clin. Endocrinol. Metab. 91: 790-792 [Full Text]  
• Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., Henley, D., Herman, P., Murday, V., Niccoli-Sire, P., Pasieka, J. L., Rohmer, V., Tucker, K., Jeunemaitre, X., Marsh, D. J., Plouin, P.-F., Robinson, B. G., for the International SDH Consortium, (2006). Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. J. Clin. Endocrinol. Metab. 91: 827-836 [Abstract] [Full Text]  
• Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., Niccoli-Sire, P., Richard, S., Rohmer, V., Sadoul, J.-L., Strompf, L., Schlumberger, M., Bertagna, X., Plouin, P.-F., Jeunemaitre, X., Gimenez-Roqueplo, A.-P. (2005). Genetic Testing in Pheochromocytoma or Functional Paraganglioma. JCO 23: 8812-8818 [Abstract] [Full Text]  
• Dahia, P. L.M., Hao, K., Rogus, J., Colin, C., Pujana, M. A.G., Ross, K., Magoffin, D., Aronin, N., Cascon, A., Hayashida, C. Y., Li, C., Toledo, S. P.A., Stiles, C. D., for the Familial Pheochromocytoma Consortium, (2005). Novel Pheochromocytoma Susceptibility Loci Identified by Integrative Genomics. Cancer Res. 65: 9651-9658 [Abstract] [Full Text]  
• Schiavi, F., Boedeker, C. C., Bausch, B., Peczkowska, M., Gomez, C. F., Strassburg, T., Pawlu, C., Buchta, M., Salzmann, M., Hoffmann, M. M., Berlis, A., Brink, I., Cybulla, M., Muresan, M., Walter, M. A., Forrer, F., Valimaki, M., Kawecki, A., Szutkowski, Z., Schipper, J., Walz, M. K., Pigny, P., Bauters, C., Willet-Brozick, J. E., Baysal, B. E., Januszewicz, A., Eng, C., Opocher, G., Neumann, H. P. H., for the European-American Paraganglioma Study Grou, (2005). Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene. JAMA 294: 2057-2063 [Abstract] [Full Text]  
• Huynh, T.-T., Pacak, K., Brouwers, F. M, Abu-Asab, M. S, Worrell, R. A, Walther, M. M, Elkahloun, A. G, Goldstein, D. S, Cleary, S., Eisenhofer, G. (2005). Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol 153: 551-563 [Abstract] [Full Text]  
• Marx, S. J., Simonds, W. F. (2005). Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes. Endocr. Rev. 26: 615-661 [Abstract] [Full Text]  
• Fassnacht, M., Weismann, D., Ebert, S., Adam, P., Zink, M., Beuschlein, F., Hahner, S., Allolio, B. (2005). AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. J. Clin. Endocrinol. Metab. 90: 4366-4370 [Abstract] [Full Text]  
• Vogel, T. W. A., Brouwers, F. M., Lubensky, I. A., Vortmeyer, A. O., Weil, R. J., Walther, M. M., Oldfield, E. H., Linehan, W. M., Pacak, K., Zhuang, Z. (2005). Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas. J. Clin. Endocrinol. Metab. 90: 3747-3751 [Abstract] [Full Text]  
• Kohane, D. S., Ingelfinger, J. R., Nimkin, K., Wu, C.-L. (2005). Case 16-2005 - A Nine-Year-Old Girl with Headaches and Hypertension. NEJM 352: 2223-2231 [Full Text]  
• Amar, L., Servais, A., Gimenez-Roqueplo, A.-P., Zinzindohoue, F., Chatellier, G., Plouin, P.-F. (2005). Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma. J. Clin. Endocrinol. Metab. 90: 2110-2116 [Abstract] [Full Text]  
• Dannenberg, H., van Nederveen, F. H., Abbou, M., Verhofstad, A. A., Komminoth, P., de Krijger, R. R., Dinjens, W. N.M. (2005). Clinical Characteristics of Pheochromocytoma Patients With Germline Mutations in SDHD. JCO 23: 1894-1901 [Abstract] [Full Text]  
• Margetts, C D E, Astuti, D, Gentle, D C, Cooper, W N, Cascon, A, Catchpoole, D, Robledo, M, Neumann, H P H, Latif, F, Maher, E R (2005). Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocr Relat Cancer 12: 161-172 [Abstract] [Full Text]  
• Garber, J. E., Offit, K. (2005). Hereditary Cancer Predisposition Syndromes. JCO 23: 276-292 [Abstract] [Full Text]  
• Kim, W. Y., Kaelin, W. G. (2004). Role of VHL Gene Mutation in Human Cancer. JCO 22: 4991-5004 [Abstract] [Full Text]  
• Eisenhofer, G, Huynh, T-T, Pacak, K, Brouwers, F M, Walther, M M, Linehan, W M, Munson, P J, Mannelli, M, Goldstein, D S, Elkahloun, A G (2004). Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11: 897-911 [Abstract] [Full Text]  
• McWhinney, S. R., Pilarski, R. T., Forrester, S. R., Schneider, M. C., Sarquis, M. M., Dias, E. P., Eng, C. (2004). Large Germline Deletions of Mitochondrial Complex II Subunits SDHB and SDHD in Hereditary Paraganglioma. J. Clin. Endocrinol. Metab. 89: 5694-5699 [Abstract] [Full Text]  
• Blake, M. A., Kalra, M. K., Maher, M. M., Sahani, D. V., Sweeney, A. T., Mueller, P. R., Hahn, P. F., Boland, G. W. (2004). Pheochromocytoma: An Imaging Chameleon. RadioGraphics 24: S87-S99 [Abstract] [Full Text]  
• Eisenhofer, G., Bornstein, S. R, Brouwers, F. M, Cheung, N.-K. V, Dahia, P. L, de Krijger, R. R, Giordano, T. J, Greene, L. A, Goldstein, D. S, Lehnert, H., Manger, W. M, Maris, J. M, Neumann, H. P H, Pacak, K., Shulkin, B. L, Smith, D. I, Tischler, A. S, Young, W. F Jr (2004). Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436 [Abstract] [Full Text]  
• Neumann, H. P. H., Pawlu, C., Peczkowska, M., Bausch, B., McWhinney, S. R., Muresan, M., Buchta, M., Franke, G., Klisch, J., Bley, T. A., Hoegerle, S., Boedeker, C. C., Opocher, G., Schipper, J., Januszewicz, A., Eng, C., for the European-American Paraganglioma Study Grou, (2004). Distinct Clinical Features of Paraganglioma Syndromes Associated With SDHB and SDHD Gene Mutations. JAMA 292: 943-951 [Abstract] [Full Text]  
• Badenhop, R F, Jansen, J C, Fagan, P A, Lord, R S A, Wang, Z G, Foster, W J, Schofield, P R (2004). The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. J. Med. Genet. 41: e99-e99 [Full Text]  
• Spatz, A., Paillerets, B. B.-d., Raymond, E. (2004). Soft Tissue Sarcomas: CASE 3. Gastrointestinal Stromal Tumor and Carney's Triad. JCO 22: 2029-2031 [Full Text]  
• Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., Bornstein, S. R. (2004). The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management. Endocr. Rev. 25: 309-340 [Abstract] [Full Text]  
• Xing, M., Vasko, V., Tallini, G., Larin, A., Wu, G., Udelsman, R., Ringel, M. D., Ladenson, P. W., Sidransky, D. (2004). BRAF T1796A Transversion Mutation in Various Thyroid Neoplasms. J. Clin. Endocrinol. Metab. 89: 1365-1368 [Abstract] [Full Text]  
• Cascon, A, Ruiz-Llorente, S, Fraga, M F, Leton, R, Telleria, D, Sastre, J, Jose Diez, J, Martinez Diaz-Guerra, G, Diaz Perez, J A, Benitez, J, Esteller, M, Robledo, M (2004). Genetic and epigenetic profile of sporadic pheochromocytomas. J. Med. Genet. 41: e30-30 [Full Text]  
• Ilias, I., Pacak, K. (2004). Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. J. Clin. Endocrinol. Metab. 89: 479-491 [Full Text]  
• Hampel, H, Sweet, K, Westman, J A, Offit, K, Eng, C (2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet. 41: 81-91 [Abstract] [Full Text]  
• Maier-Woelfle, M., Brandle, M., Komminoth, P., Saremaslani, P., Schmid, S., Locher, T., Heitz, P. U., Krull, I., Galeazzi, R. L., Schmid, C., Perren, A. (2004). A Novel Succinate Dehydrogenase Subunit B Gene Mutation, H132P, Causes Familial Malignant Sympathetic Extraadrenal Paragangliomas. J. Clin. Endocrinol. Metab. 89: 362-367 [Abstract] [Full Text]  
• Blake, M. A., Krishnamoorthy, S. K., Boland, G. W., Sweeney, A. T., Pitman, M. B., Harisinghani, M., Mueller, P. R., Hahn, P. F. (2003). Low-Density Pheochromocytoma on CT: A Mimicker of Adrenal Adenoma. Am. J. Roentgenol. 181: 1663-1668 [Abstract] [Full Text]  
• McWhinney, S. R., Boru, G., Binkley, P. K., Peczkowska, M., Januszewicz, A. A., Neumann, H. P. H., Eng, C. (2003). Intronic Single Nucleotide Polymorphisms in the RET Protooncogene Are Associated with a Subset of Apparently Sporadic Pheochromocytoma and May Modulate Age of Onset. J. Clin. Endocrinol. Metab. 88: 4911-4916 [Abstract] [Full Text]  
• Lima, J., Teixeira-Gomes, J., Soares, P., Maximo, V., Honavar, M., Williams, D., Sobrinho-Simoes, M. (2003). Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia. J. Clin. Endocrinol. Metab. 88: 4932-4937 [Abstract] [Full Text]  
• Luft, F. C. (2003). Mendelian Forms of Human Hypertension and Mechanisms of Disease. Clin Med Res 1: 291-300 [Abstract] [Full Text]  
• Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Van Kien, P. K., Corvol, P., Plouin, P.-F., Jeunemaitre, X. (2003). Mutations in the SDHB Gene Are Associated with Extra-adrenal and/or Malignant Phaeochromocytomas. Cancer Res. 63: 5615-5621 [Abstract] [Full Text]  
• Saurborn, D. P., Kruskal, J. B., Stillman, I. E., Parangi, S. (2003). Best Cases from the AFIP: Paraganglioma of the Organs of Zuckerkandl. RadioGraphics 23: 1279-1286 [Full Text]  
• Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., Nathanson, K. L. (2003). Pheochromocytoma: The Expanding Genetic Differential Diagnosis. JNCI J Natl Cancer Inst 95: 1196-1204 [Abstract] [Full Text]  
• Bravo, E. L., Tagle, R. (2003). Pheochromocytoma: State-of-the-Art and Future Prospects. Endocr. Rev. 24: 539-553 [Abstract] [Full Text]  
• Bauters, C, Vantyghem, M-C, Leteurtre, E, Odou, M-F, Mouton, C, Porchet, N, Wemeau, J-L, Proye, C, Pigny, P (2003). Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J. Med. Genet. 40: e75-75 [Full Text]  
• Hes, F. J., Hoppener, J. W. M., Lips, C. J. M. (2003). Pheochromocytoma in Von Hippel-Lindau Disease. J. Clin. Endocrinol. Metab. 88: 969-974 [Full Text]  
• Koch, C. A., Pacak, K., Chrousos, G. P. (2002). The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. J. Clin. Endocrinol. Metab. 87: 5367-5384 [Abstract] [Full Text]  
• Maher, E. R., Eng, C. (2002). The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11: 2347-2354 [Abstract] [Full Text]  
• Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rotig, A., Jeunemaitre, X. (2002). Functional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma. J. Clin. Endocrinol. Metab. 87: 4771-4774 [Abstract] [Full Text]  
• Strauchen, J. A., Neumann, H. P.H., Schipper, J., Eng, C. (2002). Germ-Line Mutations in Nonsyndromic Pheochromocytoma. NEJM 347: 854-855 [Full Text]  
• Young, A. L., Baysal, B. E., Deb, A., Young, W. F. Jr. (2002). Familial Malignant Catecholamine-Secreting Paraganglioma with Prolonged Survival Associated with Mutation in the Succinate Dehydrogenase B Gene. J. Clin. Endocrinol. Metab. 87: 4101-4105 [Abstract] [Full Text]  
• Baysal, B E (2002). Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet. 39: 617-622 [Abstract] [Full Text]  
• Dluhy, R. G. (2002). Pheochromocytoma -- Death of an Axiom. NEJM 346: 1486-1488 [Full Text]